Ascendis Pharma A/S · NASDAQ (us_market)
Healthcare · Biotechnology · Denmark
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-03-17$168.84 RISE2025-04-08$137.41 PEAK2025-06-24$179.10 99d | -18.6% 22d | Missed | Missed | — | — | +30.3% 77d | Missed |
DROP2024-09-30$149.31 RISE2025-02-10$119.49 PEAK2025-05-02$172.06 214d | -20.0% 133d | Missed | Missed | — | — | +44.0% 81d | Missed |
DROP2024-09-19$153.43 RISE2024-11-18$122.00 PEAK2025-02-18$156.19 152d | -20.5% 60d | Missed | Missed | — | — | +28.0% 92d | Missed |
DROP2024-05-02$141.10 RISE2024-09-11$112.93 PEAK2024-09-19$153.43 140d | -20.0% 132d | Missed | Missed | — | — | +35.9% 8d | Missed |
DROP2024-02-23$159.40 RISE2024-06-20$121.62 PEAK2024-07-16$140.80 144d | -23.7% 118d | Missed | Missed | — | — | +15.8% 26d | Missed |
DROP2024-02-23$159.40 RISE2024-05-20$121.07 PEAK2024-07-16$140.80 144d | -24.0% 87d | Missed | Missed | — | — | +16.3% 57d | Missed |
DROP2023-09-06$103.97 RISE2023-10-04$86.10 PEAK2023-12-28$127.36 113d | -17.2% 28d | Missed | Missed | — | — | +47.9% 85d | Missed |
DROP2023-03-29$110.58 RISE2023-07-24$86.50 PEAK2023-09-06$103.97 161d | -21.8% 117d | Missed | Missed | — | — | +20.2% 44d | Missed |
DROP2023-01-06$126.78 RISE2023-04-28$69.96 PEAK2023-05-10$97.84 124d | -44.8% 112d | Missed | Missed | — | — | +39.9% 12d | Missed |
DROP2022-08-12$110.23 RISE2022-08-30$86.10 PEAK2022-11-11$131.97 91d | -21.9% 18d | Missed | Missed | — | — | +53.3% 73d | Missed |
DROP2022-03-22$123.34 RISE2022-08-01$84.03 PEAK2022-10-06$115.90 198d | -31.9% 132d | Missed | Missed | — | — | +37.9% 66d | Missed |
DROP2022-02-09$125.00 RISE2022-06-16$78.60 PEAK2022-08-12$110.23 184d | -37.1% 127d | Missed | Missed | — | — | +40.2% 57d | Missed |
DROP2022-01-03$135.75 RISE2022-05-11$78.08 PEAK2022-08-08$98.93 217d | -42.5% 128d | Missed | Missed | — | — | +26.7% 89d | Missed |
DROP2021-11-02$164.31 RISE2022-03-11$102.18 PEAK2022-03-22$123.34 140d | -37.8% 129d | Missed | Missed | — | — | +20.7% 11d | Missed |
DROP2021-10-11$169.66 RISE2022-01-21$107.97 PEAK2022-02-09$125.00 121d | -36.4% 102d | Missed | Missed | — | — | +15.8% 19d | Missed |
1–15 / 19 1 / 2 | |||||||
European equities traded in the US as American depositary receipts were rising late Friday morning,
European equities traded in the US as American depositary receipts were rising late Friday morning,
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
Ascendis Pharma's Yorvipath and Yuviwel are driving robust pipeline momentum. Click here to read why ASND stock is a Buy.
European equities traded in the US as American depositary receipts were trending higher late Tuesday
European equities traded in the US as American depositary receipts were trending higher late Tuesday
Global-E Online enables cross-border e-commerce for retailers and brands, serving international merchants through its proprietary platform.
Global-E Online enables cross-border e-commerce for retailers and brands, serving international merchants through its proprietary platform.
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $355.
European equities traded in the US as American depositary receipts were heading higher late Monday m
European equities traded in the US as American depositary receipts were heading higher late Monday m
S&P 500 trends favor growth stocks. ASND scores perfect 10 on technicals with strong earnings acceleration, ideal for CANSLIM/Minnervini momentum strategies.
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $324 to $329.
Even though Ascendis Pharma A/S ( NASDAQ:ASND ) posted strong earnings recently, the stock hasn't reacted in a large...
Even though Ascendis Pharma A/S ( NASDAQ:ASND ) posted strong earnings recently, the stock hasn't reacted in a large...
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ASND | +1.44% | -7.43% | +5.10% | +37.63% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -1.53% | -1.71% | +8.54% | +24.94% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 3.88M | $886.69M | 0.05% | Trimmed-6.7% | 2026-03-31 |
| Wellington | fundamental | 1.76M | $402.02M | 0.08% | Unchanged | 2026-03-31 |
| TwoSigma | quant | 220.3K | $50.40M | 0.04% | Trimmed-11.1% | 2026-03-31 |
| RenTech | quant | 117.3K | $26.84M | 0.04% | New | 2026-03-31 |
| StateStreet | passive | 87.3K | $19.98M | 0.00% | Added+28.5% | 2026-03-31 |
| DEShaw | quant | 1.1K | $242.91K | 0.00% | Trimmed-99.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -0.08 | 0.27 | +429.27% |
| 2026-04-30 | 0.43 | — | — |
| 2026-02-11 | -0.24 | -0.55 | -124.49% |
| 2025-11-12 | -0.16 | -1.00 | -528.77% |
| 2025-08-07 | -1.31 | -0.64 | +51.17% |
| 2025-05-01 | -1.51 | -1.58 | -4.95% |
| 2025-02-12 | -0.93 | -0.64 | +31.38% |
| 2024-11-14 | -1.49 | -1.72 | -15.30% |
| 2024-09-03 | -1.34 | -1.91 | -42.87% |
| 2024-05-02 | -1.42 | -2.30 | -61.93% |
| 2024-02-07 | -1.76 | -1.54 | +12.65% |
| 2023-11-07 | -2.25 | -2.88 | -28.13% |
| 2023-09-05 | -2.60 | -2.16 | +16.82% |
| 2023-04-27 | -2.62 | -1.98 | +24.34% |
| 2023-02-16 | -2.55 | -3.70 | -45.33% |
| 2022-11-02 | -2.53 | -3.03 | -19.64% |